A Phase 1/2 interventional study of BMN 351 in Duchenne Muscular Dystrophy, sponsored by BioMarin Pharmaceutical. Active, not recruiting at 7 sites in 5 countries. Open to male participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by BioMarin Pharmaceutical · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical — 1 open to participants now, 2 under way, none of them phase 3. Muscular Dystrophy, Duchenne · BioMarin Pharmaceutical.
Among the 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical, this one is the only one that started in 2024, is one of 4 in phase 1/2, and was the 9th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →1 of the 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical is open now, in 5 countries. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in Italy, Netherlands, Spain and 2 more countries
Ages 4+ · Men only
By country, each count listing its studies:
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 10 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 1
First in 2009; this study’s year is marked. 1 started in 2024.
This study's enrollment of 18 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 17 across the 8 interventional studies, 269 across the 1 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
1 of the studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06280209BioMarin PharmaceuticalA Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | 2027-04-14 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.
This is Phase 1/2, open-label, multi-center study consisting of 2 parts to evaluate the safety and tolerability of BMN 351 at escalating doses in participants with Duchenne Muscular Dystrophy (DMD) with genetic mutations amenable to exon 51 skipping.
Participants will be assigned to one of three groups called cohorts (Cohort 1, 2 or 3). Cohort 1 participants are further divided into Cohort 1A and Cohort 1B. In Cohort 1A, 3 participants will receive increasing doses once every 2 weeks with a visit to assess safety measures collected the week after dosing prior to escalating doses of BMN 351. In part 2, the participants in cohort 1A will transition to once weekly dosing. The participants in Cohort 1B, 2, and 3 will initiate low, medium, and high doses of BMN 351 and continue once weekly dosing at that same dose. The study will enroll approximately 18 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1A will consist of both a single ascending dose (SAD) part and a multiple ascending dose (MAD). BMN 351 will be administered once every 2 weeks during the SAD portion of the study for up to 8 weeks and once weekly during the MAD portion for up to 89 weeks.
Drug: BMN 351
BMN 351 low dose will be administered once weekly for up to 97 weeks
Drug: BMN 351
BMN 351 medium dose will be administered once weekly for up to 73 weeks
Drug: BMN 351
BMN 351 high dose will be administered once weekly for up to 48 weeks
Drug: BMN 351
Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters).
The safety and tolerability of BMN 351 will be assessed based on the incidence of adverse and serious adverse events.
Time frame: Up to 97 weeks.
Pharmacokinetics (PK) concentration of BMN 351 in plasma, urine and muscle approximately every 8 weeks for up to 97 weeks.
Serial measurements of plasma and urine PK predose approximately hourly up to 24 hours post-infusion. Muscle PK will be measured at 13 weeks or 25 weeks only post dosing.
Time frame: Serial measurements pre and post infusion.
To evaluate the immune response to BMN 351.
Anti-BMN 351 antibodies, anti-dystrophin antibodies.
Time frame: Up to 97 weeks
To evaluate the effect of BMN 351 on physical function.
Change from baseline on 6 Minute Walk Test (6MWT).
Time frame: Change from baseline at week 25.
To evaluate the effect of BMN 351 on physical function.
Change from baseline on North Star Ambulatory Assessment (NSAA).
Time frame: Change from baseline at week 25.
Change from baseline in dystrophin expression measured by Liquid chromatography-mass spectrometry (LC-MS).
Time frame: Baseline, Week 13 or Week 25
Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.
Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 39 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →